PURPOSE: Fibroblast growth factor receptor (FGFR) 2 alterations, present in 5%-15% of intrahepatic cholangiocarcinomas (IHC), are targets of FGFR-directed therapies. Acquired resistance is common among patients who respond. Biopsies at the time of acquired resistance to targeted agents may not always be feasible and may not capture the genetic heterogeneity that could exist within a patient. We studied circulating tumor DNA (ctDNA) as a less invasive means of potentially identifying genomic mechanisms of resistance to FGFR-targeted therapies. MATERIALS AND METHODS: Serial blood samples were collected from eight patients with FGFR-altered cholangiocarcinoma for ctDNA isolation and next-generation sequencing (NGS) throughout treatment and at resistance to anti-FGFR-targeted therapy. ctDNA was sequenced using a custom ultra-deep coverage NGS panel, incorporating dual index primers and unique molecular barcodes to enable high-sensitivity mutation detection. RESULTS: Thirty-one acquired mutations in FGFR2, 30/31 located in the kinase domain, were identified at resistance in six of eight patients with detectable ctDNA. Up to 13 independent FGFR2 mutations were detected per patient, indicative of striking genomic concordance among resistant subclones. CONCLUSION: ctDNA could be an effective means to longitudinally monitor for acquired resistance in FGFR2-altered IHC. The numerous acquired genetic alterations in FGFR2 suggest frequent polyclonal mechanisms of resistance that cannot be detected from single-site tissue biopsies.
PURPOSE: Fibroblast growth factor receptor (FGFR) 2 alterations, present in 5%-15% of intrahepatic cholangiocarcinomas (IHC), are targets of FGFR-directed therapies. Acquired resistance is common among patients who respond. Biopsies at the time of acquired resistance to targeted agents may not always be feasible and may not capture the genetic heterogeneity that could exist within a patient. We studied circulating tumor DNA (ctDNA) as a less invasive means of potentially identifying genomic mechanisms of resistance to FGFR-targeted therapies. MATERIALS AND METHODS: Serial blood samples were collected from eight patients with FGFR-altered cholangiocarcinoma for ctDNA isolation and next-generation sequencing (NGS) throughout treatment and at resistance to anti-FGFR-targeted therapy. ctDNA was sequenced using a custom ultra-deep coverage NGS panel, incorporating dual index primers and unique molecular barcodes to enable high-sensitivity mutation detection. RESULTS: Thirty-one acquired mutations in FGFR2, 30/31 located in the kinase domain, were identified at resistance in six of eight patients with detectable ctDNA. Up to 13 independent FGFR2 mutations were detected per patient, indicative of striking genomic concordance among resistant subclones. CONCLUSION: ctDNA could be an effective means to longitudinally monitor for acquired resistance in FGFR2-altered IHC. The numerous acquired genetic alterations in FGFR2 suggest frequent polyclonal mechanisms of resistance that cannot be detected from single-site tissue biopsies.
Authors: Milind Javle; Maeve Lowery; Rachna T Shroff; Karl Heinz Weiss; Christoph Springfeld; Mitesh J Borad; Ramesh K Ramanathan; Lipika Goyal; Saeed Sadeghi; Teresa Macarulla; Anthony El-Khoueiry; Robin Kate Kelley; Ivan Borbath; Su Pin Choo; Do-Youn Oh; Philip A Philip; Li-Tzong Chen; Thanyanan Reungwetwattana; Eric Van Cutsem; Kun-Huei Yeh; Kristen Ciombor; Richard S Finn; Anuradha Patel; Suman Sen; Dale Porter; Randi Isaacs; Andrew X Zhu; Ghassan K Abou-Alfa; Tanios Bekaii-Saab Journal: J Clin Oncol Date: 2017-11-28 Impact factor: 44.544
Authors: Jeffrey S Ross; Kai Wang; Laurie Gay; Rami Al-Rohil; Janne V Rand; David M Jones; Hwa J Lee; Christine E Sheehan; Geoff A Otto; Gary Palmer; Roman Yelensky; Doron Lipson; Deborah Morosini; Matthew Hawryluk; Daniel V T Catenacci; Vincent A Miller; Chaitanya Churi; Siraj Ali; Philip J Stephens Journal: Oncologist Date: 2014-02-21
Authors: Maeve A Lowery; Ryan Ptashkin; Emmet Jordan; Michael F Berger; Ahmet Zehir; Marinela Capanu; Nancy E Kemeny; Eileen M O'Reilly; Imane El-Dika; William R Jarnagin; James J Harding; Michael I D'Angelica; Andrea Cercek; Jaclyn F Hechtman; David B Solit; Nikolaus Schultz; David M Hyman; David S Klimstra; Leonard B Saltz; Ghassan K Abou-Alfa Journal: Clin Cancer Res Date: 2018-05-30 Impact factor: 12.531
Authors: Lipika Goyal; Lei Shi; Leah Y Liu; Ferran Fece de la Cruz; Jochen K Lennerz; Srivatsan Raghavan; Ignaty Leschiner; Liudmila Elagina; Giulia Siravegna; Raymond W S Ng; Phuong Vu; Krushna C Patra; Supriya K Saha; Raul N Uppot; Ron Arellano; Stephanie Reyes; Takeshi Sagara; Sachie Otsuki; Brandon Nadres; Heather A Shahzade; Ipsita Dey-Guha; Isobel J Fetter; Islam Baiev; Emily E Van Seventer; Janet E Murphy; Cristina R Ferrone; Kenneth K Tanabe; Vikram Deshpande; James J Harding; Rona Yaeger; Robin K Kelley; Alberto Bardelli; A John Iafrate; William C Hahn; Cyril H Benes; David T Ting; Hiroshi Hirai; Gad Getz; Dejan Juric; Andrew X Zhu; Ryan B Corcoran; Nabeel Bardeesy Journal: Cancer Discov Date: 2019-05-20 Impact factor: 39.397
Authors: Lipika Goyal; Supriya K Saha; Leah Y Liu; Giulia Siravegna; Ignaty Leshchiner; Leanne G Ahronian; Jochen K Lennerz; Phuong Vu; Vikram Deshpande; Avinash Kambadakone; Benedetta Mussolin; Stephanie Reyes; Laura Henderson; Jiaoyuan Elisabeth Sun; Emily E Van Seventer; Joseph M Gurski; Sabrina Baltschukat; Barbara Schacher-Engstler; Louise Barys; Christelle Stamm; Pascal Furet; David P Ryan; James R Stone; A John Iafrate; Gad Getz; Diana Graus Porta; Ralph Tiedt; Alberto Bardelli; Dejan Juric; Ryan B Corcoran; Nabeel Bardeesy; Andrew X Zhu Journal: Cancer Discov Date: 2016-12-29 Impact factor: 39.397
Authors: Martin H Voss; Cinta Hierro; Rebecca S Heist; James M Cleary; Funda Meric-Bernstam; Josep Tabernero; Filip Janku; Leena Gandhi; A John Iafrate; Darrell R Borger; Nobuya Ishii; Youyou Hu; Yulia Kirpicheva; Valerie Nicolas-Metral; Anna Pokorska-Bocci; Anne Vaslin Chessex; Claudio Zanna; Keith T Flaherty; Jose Baselga Journal: Clin Cancer Res Date: 2019-02-11 Impact factor: 13.801
Authors: Ghassan K Abou-Alfa; Vaibhav Sahai; Antoine Hollebecque; Gina Vaccaro; Davide Melisi; Raed Al-Rajabi; Andrew S Paulson; Mitesh J Borad; David Gallinson; Adrian G Murphy; Do-Youn Oh; Efrat Dotan; Daniel V Catenacci; Eric Van Cutsem; Tao Ji; Christine F Lihou; Huiling Zhen; Luis Féliz; Arndt Vogel Journal: Lancet Oncol Date: 2020-03-20 Impact factor: 41.316
Authors: Yohann Loriot; Andrea Necchi; Se Hoon Park; Jesus Garcia-Donas; Robert Huddart; Earle Burgess; Mark Fleming; Arash Rezazadeh; Begoña Mellado; Sergey Varlamov; Monika Joshi; Ignacio Duran; Scott T Tagawa; Yousef Zakharia; Bob Zhong; Kim Stuyckens; Ademi Santiago-Walker; Peter De Porre; Anne O'Hagan; Anjali Avadhani; Arlene O Siefker-Radtke Journal: N Engl J Med Date: 2019-07-25 Impact factor: 91.245
Authors: Emiliano Cocco; Alison M Schram; Amanda Kulick; Sandra Misale; Helen H Won; Rona Yaeger; Pedram Razavi; Ryan Ptashkin; Jaclyn F Hechtman; Eneda Toska; James Cownie; Romel Somwar; Sophie Shifman; Marissa Mattar; S Duygu Selçuklu; Aliaksandra Samoila; Sean Guzman; Brian B Tuch; Kevin Ebata; Elisa de Stanchina; Rebecca J Nagy; Richard B Lanman; Brian Houck-Loomis; Juber A Patel; Michael F Berger; Marc Ladanyi; David M Hyman; Alexander Drilon; Maurizio Scaltriti Journal: Nat Med Date: 2019-08-12 Impact factor: 53.440
Authors: Aparna R Parikh; Ignaty Leshchiner; Liudmila Elagina; Lipika Goyal; Chaya Levovitz; Giulia Siravegna; Dimitri Livitz; Kahn Rhrissorrakrai; Elizabeth E Martin; Emily E Van Seventer; Megan Hanna; Kara Slowik; Filippo Utro; Christopher J Pinto; Alicia Wong; Brian P Danysh; Ferran Fece de la Cruz; Isobel J Fetter; Brandon Nadres; Heather A Shahzade; Jill N Allen; Lawrence S Blaszkowsky; Jeffrey W Clark; Bruce Giantonio; Janet E Murphy; Ryan D Nipp; Eric Roeland; David P Ryan; Colin D Weekes; Eunice L Kwak; Jason E Faris; Jennifer Y Wo; François Aguet; Ipsita Dey-Guha; Mehlika Hazar-Rethinam; Dora Dias-Santagata; David T Ting; Andrew X Zhu; Theodore S Hong; Todd R Golub; A John Iafrate; Viktor A Adalsteinsson; Alberto Bardelli; Laxmi Parida; Dejan Juric; Gad Getz; Ryan B Corcoran Journal: Nat Med Date: 2019-09-09 Impact factor: 53.440
Authors: Qibiao Wu; Yuanli Zhen; Lei Shi; Phuong Vu; Patricia Greninger; Ramzi Adil; Joshua Merritt; Regina Egan; Meng-Ju Wu; Xunqin Yin; Cristina R Ferrone; Vikram Deshpande; Islam Baiev; Christopher J Pinto; Daniel E McLoughlin; Charlotte S Walmsley; James R Stone; John D Gordan; Andrew X Zhu; Dejan Juric; Lipika Goyal; Cyril H Benes; Nabeel Bardeesy Journal: Cancer Discov Date: 2022-05-02 Impact factor: 38.272